12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches

Table 1 (abstract P24). Data on primary and secondary outcomes Safety: Exposure-adjusted Subject Incidence Rates of Treatment-emergent Adverse Events Occurring in > 2/100 subject-years for total erenumab (Safety Analysis Set)

Adverse event	Erenumab 70 mg/140 mg (N=609), n (%) / e [r]
Viral upper respiratory tract infection	96 (15.8) / 586.0 [16.4]
Upper respiratory tract infection	45 (7.4) / 624.5 [7.2]
Sinusitis	44 (7.2) / 620.4 [7.1]
Arthralgia	27 (4.4) / 636.7 [4.2]
Migraine	26 (4.3) / 638.5 [4.1]

% = n / N x 100; N = number of subjects exposed to erenumab in OLE; n = number of subjects reporting at least 1 occurrence of an adverse event; r = exposure-adjusted subject rate per 100 subject-years (n / e x 100)
e = sum across all subjects, the total time at risk in the study in years

ISSN: 1129-2377